Quince Therapeutics, Inc. (QNCX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
QNCX currently has 16.3M outstanding shares. with significant dilution risk as 30.4M authorized shares could dilute existing holders by 186.8%. The company has significantly diluted shareholders by 226.81% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 11, 2026 |
10-Q filing | 16.3M shares outstanding |
16M | 30M |
| Apr 10, 2026 |
10-K filing | 163.0M shares outstanding |
160M | 0 |
| Nov 12, 2025 |
10-Q filing | 54.0M shares outstanding |
54M | 0 |
| Aug 11, 2025 |
10-Q filing | 53.7M shares outstanding |
54M | 0 |
| Jul 25, 2025 |
S-3 filing: This S-3 filing relates to the proposed resale from time to time by the selling stockholders of up to 2,000,000 shares of common stock issuable upon exercise of pre-funded warrants, up to 8,671,928 shares of common stock issuable upon exercise of common stock warrants, and up to 6,671,928 shares of common stock. |
44M | 2.8M |
| May 13, 2025 |
10-Q filing | 43.9M shares outstanding |
44M | 0 |
| Mar 24, 2025 |
10-K filing | 43.3M shares outstanding |
43M | 0 |
| Dec 18, 2024 |
S-3 filing: The company is offering shares of its common stock having an aggregate offering price of up to $75.0 million through an at-the-market offering. The company intends to use the net proceeds for working capital and general corporate purposes. |
43M | 0 |
| Nov 13, 2024 |
10-Q filing | 43.2M shares outstanding |
43M | 0 |
| Aug 13, 2024 |
10-Q filing | 43.1M shares outstanding |
43M | 0 |
| May 13, 2024 |
10-Q filing | 43.0M shares outstanding |
43M | 0 |
| Apr 01, 2024 |
10-K filing | 43.2M shares outstanding |
43M | 0 |
| Nov 14, 2023 |
10-Q filing | 42.9M shares outstanding |
43M | 0 |
| Aug 03, 2023 |
10-Q filing | 35.9M shares outstanding |
36M | 0 |
| May 15, 2023 |
10-Q filing | 35.9M shares outstanding |
36M | 0 |
| Mar 15, 2023 |
10-K filing | 33.5M shares outstanding |
33M | 0 |
| Nov 09, 2022 |
10-Q filing | 35.6M shares outstanding |
36M | 0 |
| Aug 09, 2022 |
10-Q filing | 36.1M shares outstanding |
36M | 0 |
| May 10, 2022 |
10-Q filing | 30.2M shares outstanding |
30M | 0 |
| Mar 04, 2022 |
POS AM filing: The filing is a POS AM filing indicating the company may offer and sell a combination of securities with a total value of up to $150 million and also an ATM offering through Jefferies. |
30M | 0 |
| Mar 01, 2022 |
10-K filing | 30.1M shares outstanding |
30M | 0 |
| Oct 29, 2021 |
10-Q filing | 29.9M shares outstanding |
30M | 0 |
| Aug 06, 2021 |
10-Q filing | 29.7M shares outstanding |
30M | 0 |
| May 06, 2021 |
10-Q filing | 29.6M shares outstanding |
30M | 0 |
| Mar 01, 2021 |
10-K filing | 29.6M shares outstanding |
30M | 0 |
| Nov 12, 2020 |
10-Q filing | 29.5M shares outstanding |
29M | 0 |
| Aug 14, 2020 |
10-Q filing | 29.5M shares outstanding |
29M | 0 |
| May 12, 2020 |
10-Q filing | 29.4M shares outstanding |
29M | 0 |
| Apr 07, 2020 |
S-1 filing: This S-1 filing describes the sale of Series B redeemable convertible preferred stock and the resale of common stock by selling stockholders. |
29M | 0 |
| Mar 16, 2020 |
10-K filing | 29.4M shares outstanding |
29M | 0 |